{"id":745009,"date":"2014-04-04T07:00:00","date_gmt":"2014-04-04T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\/"},"modified":"2023-03-22T00:04:57","modified_gmt":"2023-03-22T04:04:57","slug":"merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\/","title":{"rendered":"Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth"},"content":{"rendered":"<p class=\"bwalignc\">       Post-partum Hemorrhage Is Leading Cause of Mothers Dying     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      Ferring Pharmaceuticals today announced their collaboration with the<br \/>\n      World Health Organization (WHO) to advance a new, proprietary<br \/>\n      formulation of carbetocin, used to prevent excessive bleeding<br \/>\n      (post-partum hemorrhage) in women after childbirth, that is designed to<br \/>\n      be stable at room temperature, even in hot and tropical climates (ICH<br \/>\n      climatic zone IV). Currently, oxytocin, the standard medicine<br \/>\n      administered for the prevention of excessive bleeding, is<br \/>\n      temperature-sensitive and requires sustained cold distribution and<br \/>\n      storage in hot climates. The WHO will conduct a multi-country clinical<br \/>\n      study to evaluate the effectiveness of room-temperature-stable<br \/>\n      carbetocin, as compared to oxytocin. The development of a medicine that<br \/>\n      can be stored at room temperature has the potential to significantly<br \/>\n      improve management of bleeding following childbirth in the many areas of<br \/>\n      the world where cold storage is difficult to achieve and maintain, and<br \/>\n      thereby help reduce maternal deaths in those areas.\n    <\/p>\n<p>\n      Starting this year, the study will take place in 12 countries around the<br \/>\n      world and enroll approximately 29,000 women. If the results of the study<br \/>\n      are positive, the organizations will work together with the aim of<br \/>\n      making the medicine available in developing countries that have a high<br \/>\n      burden of maternal mortality at an affordable and sustainable<br \/>\n      public-sector price.\n    <\/p>\n<p>\n      \u201cMothers hold the future in their hands. That\u2019s why Merck has taken on<br \/>\n      our 10-year, $500 million fight against maternal mortality,\u201d said<br \/>\n      Kenneth C. Frazier, chairman and chief executive officer, Merck.<br \/>\n      \u201cWorking with our partners, we can help make a better solution a<br \/>\n      reality. It would be a real breakthrough to help prevent the number-one<br \/>\n      cause of women dying in childbirth in the most vulnerable parts of the<br \/>\n      globe.\u201d Through its <i>Merck for Mothers<\/i> initiative, Merck is<br \/>\n      applying its scientific and business expertise \u2013 as well as its<br \/>\n      financial resources \u2013 to reduce maternal mortality around the world.\n    <\/p>\n<p>\n      \u201cFew tragedies compare to the death of a mother during childbirth.<br \/>\n      Obstetric treatments that benefit mother and baby are a key focus of our<br \/>\n      efforts at Ferring. Ferring originally developed carbetocin and received<br \/>\n      the indication for the prevention of post-partum hemorrhage more than a<br \/>\n      decade ago. Ferring is delighted to join with the WHO and Merck in this<br \/>\n      project that aims to make the benefits of carbetocin available in areas<br \/>\n      of the world where cold storage is not readily available,\u201d said Michel<br \/>\n      L. Pettigrew, President of the Executive Board and COO, Ferring Group.\n    <\/p>\n<p>\n      <b>About Carbetocin<\/b>\n    <\/p>\n<p>\n      Carbetocin is not available in the United States. The WHO study of<br \/>\n      room-temperature-stable carbetocin will take place in Argentina, Brazil,<br \/>\n      Egypt, India, Kenya, Nigeria, Pakistan, Singapore, South Africa,<br \/>\n      Thailand, Uganda and the United Kingdom.\n    <\/p>\n<p>\n      <b>About Ferring Pharmaceuticals<\/b>\n    <\/p>\n<p>\n      Ferring Pharmaceuticals is a research-driven, specialty<br \/>\n      biopharmaceutical group, headquartered in Switzerland, and active in<br \/>\n      global markets. The company identifies, develops and markets innovative<br \/>\n      products in the areas of reproductive health, urology, gastroenterology<br \/>\n      and endocrinology. Ferring\u2019s obstetric portfolio (available in various<br \/>\n      countries outside the USA) includes carbetocin, a medicine which<br \/>\n      prevents post-partum hemorrhage, atosiban, a medicine which delays<br \/>\n      imminent preterm birth and dinoprostone and misoprostol to be used in<br \/>\n      connection with labour induction. Ferring has its own operating<br \/>\n      subsidiaries in 55 countries and markets its products in more than 100<br \/>\n      countries. To learn more about Ferring or its products please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ferring.com&amp;esheet=50838216&amp;newsitemid=20140404005156&amp;lan=en-US&amp;anchor=www.ferring.com&amp;index=1&amp;md5=8770c534a628d41c927cee4576699e41\" rel=\"nofollow\">www.ferring.com<\/a>.\n    <\/p>\n<p>\n      <b>About <i>Merck for Mothers<\/i><\/b>\n    <\/p>\n<p>\n      Every two minutes, a woman dies from complications related to pregnancy<br \/>\n      and childbirth. If nothing is done an estimated three million women may<br \/>\n      die from complications of pregnancy and childbirth in the next decade.<br \/>\n      Most of these deaths are preventable. While the burden falls most<br \/>\n      heavily on the developing world, certain communities in the United<br \/>\n      States and other developed nations are suffering significant and<br \/>\n      worsening rates of maternal death.\n    <\/p>\n<p>\n      <i>Merck for Mothers<\/i> is a 10-year, $500 million initiative focused<br \/>\n      on creating a world where no woman has to die from complications of<br \/>\n      pregnancy and childbirth. Drawing on the company&#8217;s history of<br \/>\n      discovering innovative, life-saving medicines and vaccines, <i>Merck for<br \/>\n      Mothers<\/i> is applying Merck&#8217;s scientific and business expertise \u2013 as<br \/>\n      well as its financial resources and experience in taking on tough global<br \/>\n      healthcare challenges \u2013 to reduce maternal mortality around the world.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merckformothers.coma&amp;esheet=50838216&amp;newsitemid=20140404005156&amp;lan=en-US&amp;anchor=www.merckformothers.com&amp;index=2&amp;md5=65f43a0b0bd9bf7346faa1b22aa3ca9b\" rel=\"nofollow\">www.merckformothers.com<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckformothers&amp;esheet=50838216&amp;newsitemid=20140404005156&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=dcbf64f71c304af47b7038491e2d3cd1\" rel=\"nofollow\">Facebook<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50838216&amp;newsitemid=20140404005156&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=201249c33164d0d88af8d908d1601ac6\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=50838216&amp;newsitemid=20140404005156&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=b4bf5849ea7126cf7bfca78ab3fd1bee\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=50838216&amp;newsitemid=20140404005156&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=566adba95fbaf0dd066388213a49df4e\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=50838216&amp;newsitemid=20140404005156&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=5e5cee02fa6758e244304f9d3b905b3e\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50838216&amp;newsitemid=20140404005156&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=ab18701dabf5c7cab8d7d0d42a7fc85b\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140404005156r1&amp;sid=hq1ny1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20140404005156\/en\/\" rel=\"nofollow\">http:\/\/www.businesswire.com\/multimedia\/home\/20140404005156\/en\/<\/a><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Jennifer Allen Woodruff, 267-305- 3550<br \/>or<br \/>Lainie        Keller, 908-423-4187<br \/>or<br \/>Investor:<br \/>Carol Ferguson,        908-423-4465<br \/>or<br \/>Ferring Media:<br \/>Helen Gallagher, +41 58        301 0051<br \/>or<br \/>Patrick Gorman, +41 58 301 0053     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Post-partum Hemorrhage Is Leading Cause of Mothers Dying Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Ferring Pharmaceuticals today announced their collaboration with the World Health Organization (WHO) to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding (post-partum hemorrhage) in women after childbirth, that is designed to be stable at room temperature, even in hot and tropical climates (ICH climatic zone IV). Currently, oxytocin, the standard medicine administered for the prevention of excessive bleeding, is temperature-sensitive and requires sustained cold distribution and storage in hot climates. The WHO will conduct a multi-country clinical study to evaluate the effectiveness of room-temperature-stable carbetocin, as compared to oxytocin. The development of a medicine that can be stored at room temperature has the potential to significantly improve management of bleeding following childbirth in the many areas of<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745009","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Post-partum Hemorrhage Is Leading Cause of Mothers Dying Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Ferring Pharmaceuticals today announced their collaboration with the World Health Organization (WHO) to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding (post-partum hemorrhage) in women after childbirth, that is designed to be stable at room temperature, even in hot and tropical climates (ICH climatic zone IV). Currently, oxytocin, the standard medicine administered for the prevention of excessive bleeding, is temperature-sensitive and requires sustained cold distribution and storage in hot climates. The WHO will conduct a multi-country clinical study to evaluate the effectiveness of room-temperature-stable carbetocin, as compared to oxytocin. The development of a medicine that can be stored at room temperature has the potential to significantly improve management of bleeding following childbirth in the many areas of\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:57+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140404005156r1&amp;sid=hq1ny1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\\\/\",\"name\":\"Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140404005156r1&amp;sid=hq1ny1&amp;distro=nx\",\"datePublished\":\"2014-04-04T07:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140404005156r1&amp;sid=hq1ny1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140404005156r1&amp;sid=hq1ny1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\/","og_locale":"en_US","og_type":"article","og_title":"Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth - Merck.com","og_description":"Post-partum Hemorrhage Is Leading Cause of Mothers Dying Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Ferring Pharmaceuticals today announced their collaboration with the World Health Organization (WHO) to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding (post-partum hemorrhage) in women after childbirth, that is designed to be stable at room temperature, even in hot and tropical climates (ICH climatic zone IV). Currently, oxytocin, the standard medicine administered for the prevention of excessive bleeding, is temperature-sensitive and requires sustained cold distribution and storage in hot climates. The WHO will conduct a multi-country clinical study to evaluate the effectiveness of room-temperature-stable carbetocin, as compared to oxytocin. The development of a medicine that can be stored at room temperature has the potential to significantly improve management of bleeding following childbirth in the many areas of","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:57+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140404005156r1&amp;sid=hq1ny1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\/","name":"Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140404005156r1&amp;sid=hq1ny1&amp;distro=nx","datePublished":"2014-04-04T07:00:00+00:00","dateModified":"2023-03-22T04:04:57+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140404005156r1&amp;sid=hq1ny1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140404005156r1&amp;sid=hq1ny1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-ferring-pharmaceuticals-and-the-world-health-organization-working-together-to-prevent-excessive-bleeding-in-women-after-childbirth\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"0cf770b7-eb32-45b6-8eb4-94e35ee10e29","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2014\/04\/1\/ferring_logo_jpg-5B1-5D.jpg","size":"62886","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2014\/04\/1\/logo_merck-logo.jpg","size":"13027","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Ferring-Pharmaceuticals-and-the-World-Health-Organization-Working-Together-to-Prevent-Excessive-Bleeding-in-Women-after-Childbi-26MD4.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745009\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745009"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}